Barriers to antiviral treatment in hepatitis C infected intravenous drug users.

@article{Gazdag2010BarriersTA,
  title={Barriers to antiviral treatment in hepatitis C infected intravenous drug users.},
  author={G{\'a}bor Gazdag and Gergely Horv{\'a}th and Olga Szab{\'o} and G{\'a}bor S{\'a}ndor Ungvari},
  journal={Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology},
  year={2010},
  volume={12 4},
  pages={
          459-62
        }
}
BACKGROUND Nowadays intravenous drug use is the main source of hepatitis C transmission, but only a small proportion of those who acquired infection via intravenous drug use receive antiviral treatment. AIM to assess the barriers of access to antiviral treatment of infected intravenous drug users. METHODS A retrospective chart review was carried out in a hepatology outpatient clinic including all hepatitis C infected intravenous drug users in a 3-year period. RESULTS Only one-third of the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Managing chronic hepatitis C acquired through intravenous drug use.

QJM : monthly journal of the Association of Physicians • 2001
View 4 Excerpts
Highly Influenced

Protocol for the antiviral treatment of hepatitis C

PF Renault, JH Hoofnagle, Y Park
Orv Hetil • 2010

HIV- és hepatitiszprevalenciák alakulása az intravénás használók között. (Tendencies of HIV and hepatitis prevalence in intravenous drug

IG Takács
Felvinczy K, Nyírády A, eds. Drogpolitika számokban. (Drug policy in numbers.) Budapest: L’Harmattan; • 2009
View 1 Excerpt

Patient information for liver biopsy: impact of a video movie.

Gastroenterologie clinique et biologique • 2007
View 1 Excerpt